We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+3.75%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
Cap. Flow
-$282M
Cap. Flow %
-9.39%
Top 10 Hldgs %
30.38%
Holding
102
New
28
Increased
19
Reduced
31
Closed
14

Top Buys

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$56.7M
2
GH icon
Guardant Health
GH
+$50.2M
3
GENB
Generate Biomedicines
GENB
+$43.9M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$43.2M
5
ARGX icon
argenx
ARGX
+$42.2M

Top Sells

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$82.6M
2
ALGN icon
Align Technology
ALGN
+$59.5M
3
CGON icon
CG Oncology
CGON
+$50.2M
4
RAPT
RAPT Therapeutics
RAPT
+$31.5M
5
LEGN icon
Legend Biotech
LEGN
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.27%
2 Miscellaneous 12.42%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRUG
26
Bright Minds Biosciences
DRUG
$714M
$39.4M 1.31%
539,708
+215,350
+66% +$17.3M
CDNA icon
27
CareDx
CDNA
$2.58B
$37.7M 1.26%
2,173,146
+587,926
+37% +$11.1M
ISRG icon
28
Intuitive Surgical
ISRG
$132B
$35.6M 1.19%
77,297
-6,120
-7% -$3.1M
INSP icon
29
Inspire Medical Systems
INSP
$1.78B
$34.9M 1.17%
677,570
+136,680
+25% +$9.57M
PEN icon
30
Penumbra
PEN
$12.7B
$34.6M 1.15%
105,352
-4,800
-4% -$1.63M
TMDX icon
31
Transmedics
TMDX
$3.07B
$32.7M 1.09%
329,391
+14,050
+4% +$1.83M
SLNO
32
DELISTED
Soleno Therapeutics
SLNO
$32.1M 1.07%
959,259
-228,600
-19% -$8.96M
DYN icon
33
Dyne Therapeutics
DYN
$4.68B
$30.5M 1.02%
1,681,998
+203,669
+14% +$3.51M
MRVI icon
34
Maravai LifeSciences
MRVI
$1.14B
$29M 0.97%
10,240,164
+1,886,877
+23% +$6.4M
ILMN icon
35
Illumina
ILMN
$32.6B
$28.3M 0.94%
229,215
-40,458
-15% -$5.31M
KYMR icon
36
Kymera Therapeutics
KYMR
$9.82B
$28.1M 0.94%
337,559
-116,700
-26% -$9.24M
BMRN icon
37
BioMarin Pharmaceuticals
BMRN
$12.5B
$28.1M 0.94%
497,020
-104,500
-17% -$6.09M
NRIX icon
38
Nurix Therapeutics
NRIX
$2.72B
$27.1M 0.91%
1,750,766
-433,098
-20% -$7.18M
RYTM icon
39
Rhythm Pharmaceuticals
RYTM
$7.38B
$27M 0.9%
+310,628
New +$30.2M
DHR icon
40
Danaher
DHR
$152B
$26.4M 0.88%
139,327
+21,100
+18% +$4.49M
ESTA icon
41
Establishment Labs
ESTA
$2.11B
$26.3M 0.88%
+463,600
New +$31.7M
TECX
42
Tectonic Therapeutic
TECX
$696M
$26.2M 0.87%
847,151
-80,373
-9% -$1.98M
NTRA icon
43
Natera
NTRA
$47B
$25.8M 0.86%
129,000
+17,500
+16% +$3.77M
CRVS icon
44
Corvus Pharmaceuticals
CRVS
$1.19B
$25.6M 0.86%
+1,752,798
New +$28M
FULC icon
45
Fulcrum Therapeutics
FULC
$294M
$24M 0.8%
3,134,922
+73,700
+2% +$684K
ZURA icon
46
Zura Bio
ZURA
$548M
$23.7M 0.79%
3,988,989
+808,600
+25% +$4.88M
ATEC icon
47
Alphatec Holdings
ATEC
$1.46B
$23.6M 0.79%
+2,172,725
New +$31.6M
DMRA
48
Damora Therapeutics
DMRA
$1.79B
$23.2M 0.77%
+894,846
New +$23M
BSX icon
49
Boston Scientific
BSX
$67.9B
$21.7M 0.73%
+346,467
New +$27.7M
VERA icon
50
Vera Therapeutics
VERA
$2.46B
$21.1M 0.7%
523,824
-260,918
-33% -$11.2M
1
2
3 4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q1 2026 Portfolio in Review

As of Q1 2026, Braidwell held 102 positions worth $3B, down 4.1% from $3.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Braidwell withdrew a net $282M in Q1 2026, closing 14 positions and reducing 31 holdings. Its most notable exit was Align Technology, an estimated $59.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Braidwell opened a new position in Guardant Health worth $46.2M.

  • Braidwell's largest Q1 2026 buy was Guardant Health: 499,712 shares worth $46.2M.
  • Braidwell added most to iRhythm Holdings in Q1 2026, an estimated $56.7M increase.
  • Braidwell's biggest Q1 2026 reduction was Edgewise Therapeutics, cutting an estimated $82.6M.
  • Braidwell fully exited Align Technology in Q1 2026, selling an estimated $59.5M.
  • Braidwell's ten largest holdings make up 30% of its $3B portfolio in Q1 2026.
  • Braidwell opened 28 new positions and closed 14 in Q1 2026.
  • Braidwell's portfolio value fell 4.1% quarter-over-quarter to $3B.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.